Skip to Main Content

Dr. Stephen Gitelman is a pediatric endocrinologist who serves as director of UCSF's pediatric diabetes program. He oversees the multidisciplinary team of pediatric diabetes experts who provide comprehensive care to more than 800 children, adolescents and young adults with type 1 and type 2 diabetes. His expertise includes the latest approaches to helping patients achieve optimal metabolic control, such as the insulin pump, continuous glucose sensor and novel insulin analogues.

In his research, Gitelman aims to better understand the cause for immune-mediated destruction of insulin-producing beta cells, as well as to find safe, effective ways to alter the natural course of diabetes. He serves as director for UCSF's participation in the type 1 diabetes research network TrialNet, an international project with funding from the National Institutes of Health. He is also an investigator in the Immune Tolerance Network, for which he oversees clinical trials of therapies to preserve beta cell function.

Gitelman earned an undergraduate degree at Princeton University, where he graduated summa cum laude. He completed his medical degree at the University of North Carolina at Chapel Hill. He completed a residency in pediatrics and a fellowship in pediatric endocrinology at UCSF, where he holds the Mary B. Olney, MD/KAK Distinguished Professorship in Pediatric Diabetes and Clinical Research.

  • Education

    University of North Carolina School of Medicine, MD, 1984

  • Residencies

    UCSF, Pediatrics, 1987

  • Fellowships

    UCSF, Pediatric Endocrinology, 1990

  • Board Certifications

    Pediatric Endocrinology, American Board of Pediatrics

  • Academic Title

    Professor

Where I see patients (2)

    Decorative Caduceus

    STOP-T1D Low-Dose (ATG)

    The primary outcome is the elapsed time from random treatment assignment to the development of diabetes or time of last contact among those randomized

    Recruiting

    More about this study
    Decorative Caduceus

    Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

    The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab compared to those participan...

    Recruiting

    More about this study
    Decorative Caduceus

    Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1...

    The primary outcome of interest is the area under the stimulated C-peptide curve over the 2-hour mixed meal glucose tolerance test conducted at the 12-month visit (Y_AUC) over the 2-hour mixed meal glucose tolerance test conducted...

    Recruiting

    More about this study
    Decorative Caduceus

    Type 1 Diabetes Extension Study

    Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal ...

    Recruiting

    More about this study
    See all clinical trials

    Fetal surgery firsts

    The first open fetal surgery in the world was performed at UCSF in the early 1980s.

    Share